The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID
This is a collaborative study between Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim Pharmaceuticals to determine the effect of Nintedanib on slowing the rate of lung fibrosis in patients who have been diagnosed with COVID-19, and have ongoing lung inj...
Age: 18 years - 66+
Gender: All
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
Scarring of the lung, termed pulmonary fibrosis (PF), is a chronic, progressive, and usually fatal disorder. While two anti-fibrotic drugs have recently been approved for treating PF of unknown cause (idiopathic pulmonary fibrosis or IPF), neither drug is curative, and ...
Age: 40 years - 66+
Gender: All
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
The long-term goal is to study the safety and effectiveness of hormonal contraception for women with cystic fibrosis (CF) and contribute to national guidelines that the Cystic Fibrosis Foundation and the Centers for Disease Control and Prevention (CDC) provide to clinic...
Age: 18 - 45 years
Gender: Female
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of
recombinant human pentraxin-2 (rhPTX-2; PRM-151) compared with placebo in participants with
idiopathic pulmonary fibrosis (IPF).
Age: 40 - 85 years
Gender: All
Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy
Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator
(CFTR) modulator therapies in treating CF, it is still largely unknown whether or not other
chronic therapies can be safely stopped. The SIMPLIFY study is being done to test whe...
Age: 12 years - 66+
Gender: All
Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis
The primary objective of this study is to evaluate whether cilofexor reduces the risk of
fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
Age: 18 - 75 years
Gender: All
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747)
can lead to histological improvement in fibrosis with no worsening of NASH in adults with
compensated cirrhosis due to NASH.
Age: 18 years - 66+
Gender: All
Assessment of Portal Hypertension With Multiparametric MRI
The purpose of this study is to determine whether new multiparametric magnetic resonance
imaging (MRI) methods (including diffusion-weighted MRI, dynamic contrast-enhanced MRI, MR
elastography and phase-contrast imaging) can be useful in assessing liver damage and deg...
Age: 18 years - 66+
Gender: All
Standardized Treatment of Pulmonary Exacerbations II
Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during
which symptoms of lung infection increase and lung function decreases. These pulmonary
exacerbations are treated with varying antibiotics for varying time periods based on need...
Age: 18 years - 66+
Gender: All
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
Primary Biliary Cholangitis (PBC) is a serious, life-threatening, bile acid related liver
disease of unknown cause. Without treatment, it frequently progresses to liver fibrosis and
eventual cirrhosis requiring liver transplantation or resulting in death. The invest...
Age: 18 years - 66+
Gender: All